| NCT00892242 | Adenocarcinoma | Drug: Zoledronic acid | Washington University School of Medicine | Phase 1 | 2009-12-01 | 2014-09-19 |
| NCT01204203 | Mesothelioma | Drug: Zometa | University of Alabama at Birmingham|Novartis Pharmaceuticals | Phase 2 | 2009-06-01 | 2016-05-20 |
| NCT00512993 | Breast Cancer | Drug: Zoledronic acid | German Breast Group|Austrian Breast & Colorectal Cancer Study Group|Novartis Pharmaceuticals | Phase 3 | 2004-12-01 | 2015-03-04 |
| NCT00982124 | Osteogenesis Imperfecta | Drug: Zoledronic Acid | Shriners Hospitals for Children|Novartis | Phase 3 | 2007-10-01 | 2016-04-18 |
| NCT00566618 | Breast Cancer|Bone Metastases | Drug: Dasatinib|Drug: Zoledronic Acid | M.D. Anderson Cancer Center|Bristol-Myers Squibb | Phase 1|Phase 2 | 2007-11-01 | 2016-12-08 |
| NCT01788176 | Complex Regional Pain Syndromes | Drug: Zoledronic acid|Drug: Placebo | University of Sao Paulo General Hospital|Novartis | Phase 2 | 2013-12-01 | 2013-02-08 |
| NCT02042872 | Disuse Osteoporosis | Drug: Zoledronic acid | James J. Peters Veterans Affairs Medical Center|Kessler Institute for Rehabilitation | Phase 4 | 2006-05-01 | 2015-05-05 |
| NCT00237146 | Prostate Cancer | Drug: Zoledronic acid | Novartis Pharmaceuticals|Novartis | Phase 4 | 2003-11-01 | 2017-02-21 |
| NCT01197300 | Osteoporosis | Drug: zoledronic acid | Novartis Pharmaceuticals|Novartis | Phase 3 | 2010-10-01 | 2016-06-10 |
| NCT00889590 | Giant Cell Tumor of Bone|Osteoclastoma | Drug: Zoledronic acid | Leiden University Medical Center | Phase 2 | 2008-12-01 | 2016-01-25 |
| NCT00712985 | Breast Cancer | Drug: Zometa | Milton S. Hershey Medical Center|Novartis | Phase 3 | 2005-09-01 | 2014-03-24 |
| NCT02123264 | Arthritis, Rheumatoid | Drug: Zoledronic acid | Carmen G贸mez-Vaquero|Hospital Universitari de Bellvitge | Phase 3 | 2014-05-01 | 2016-02-21 |
| NCT00145327 | Osteoporosis | Drug: Zoledronic Acid|Drug: Placebo | Novartis | Phase 3 | 2005-05-01 | 2011-06-24 |
| NCT00172042 | Non-Small-Cell Lung Cancer | Drug: Zoledronic acid 4 mg | Novartis Pharmaceuticals|Novartis | Phase 3 | 2005-03-01 | 2015-04-13 |
| NCT01642901 | Spinal Cord Injury | Drug: Zoledronic acid|Drug: normal saline 0.9% | Thomas Jefferson University|Department of Health and Human Services | Phase 3 | 2012-05-01 | 2017-01-12 |
| NCT00361595 | Osteoporosis | Drug: zoledronic acid | The Cleveland Clinic|Novartis Pharmaceuticals | | 2006-08-01 | 2010-12-14 |
| NCT00376740 | Breast Cancer | Drug: zoledronic acid | Soroka University Medical Center|Tel-Aviv Sourasky Medical Center | Phase 3 | 2005-09-01 | 2011-08-22 |
| NCT01004510 | Malignant Pleural Effusion|Non Small Cell Lung Cancer | Drug: zoledronic acid | Peter Bushunow MD|Novartis Pharmaceuticals|Rochester General Hospital | Phase 2 | 2009-11-01 | 2012-11-05 |
| NCT00216151 | Multiple Myeloma | Drug: Zoledronic Acid | Hoosier Cancer Research Network|Novartis Pharmaceuticals|Walther Cancer Institute | Phase 2 | 2005-06-01 | 2011-04-28 |
| NCT01016093 | Beta-Thalassemia|Bone Marrow Transplantation | Drug: Zoledronic acid|Drug: Placebo | Tehran University of Medical Sciences|Novartis | Phase 2|Phase 3 | 2009-11-01 | 2011-07-25 |
| NCT02480634 | Non-small Cell Lung Cancer|Bone Metastasis | Drug: Zoledronic acid|Radiation: Radiotherapy | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 4 | 2016-06-01 | 2016-06-09 |
